A detailed history of Moors & Cabot, Inc. transactions in Novartis Ag stock. As of the latest transaction made, Moors & Cabot, Inc. holds 28,559 shares of NVS stock, worth $2.98 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares
28,559
Previous 28,809 0.87%
Holding current value
$2.98 Million
Previous $3.07 Million 7.08%
% of portfolio
0.17%
Previous 0.17%

Shares

33 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$106.13 - $120.89 $26,532 - $30,222
-250 Reduced 0.87%
28,559 $3.28 Million
Q2 2024

Aug 09, 2024

SELL
$92.57 - $107.37 $16,940 - $19,648
-183 Reduced 0.63%
28,809 $3.07 Million
Q1 2024

May 08, 2024

SELL
$95.27 - $108.47 $52,398 - $59,658
-550 Reduced 1.86%
28,992 $2.8 Million
Q4 2023

Feb 14, 2024

BUY
$92.27 - $101.54 $23,067 - $25,385
250 Added 0.85%
29,542 $2.98 Million
Q3 2023

Nov 07, 2023

BUY
$94.73 - $105.13 $23,682 - $26,282
250 Added 0.86%
29,292 $2.98 Million
Q2 2023

Aug 09, 2023

SELL
$92.52 - $104.91 $92,982 - $105,434
-1,005 Reduced 3.34%
29,042 $2.93 Million
Q1 2023

May 04, 2023

BUY
$80.03 - $92.81 $21,207 - $24,594
265 Added 0.89%
30,047 $2.76 Million
Q4 2022

Feb 09, 2023

BUY
$75.55 - $92.52 $27,198 - $33,307
360 Added 1.22%
29,782 $2.7 Million
Q4 2022

Feb 06, 2023

SELL
$75.55 - $92.52 $113,173 - $138,594
-1,498 Reduced 4.84%
29,422 $2.67 Million
Q3 2022

Nov 07, 2022

SELL
$74.61 - $87.26 $22,159 - $25,916
-297 Reduced 0.95%
30,920 $2.35 Million
Q2 2022

Aug 08, 2022

BUY
$80.52 - $93.75 $20,291 - $23,625
252 Added 0.81%
31,217 $2.64 Million
Q1 2022

May 13, 2022

BUY
$80.11 - $90.62 $45,101 - $51,019
563 Added 1.85%
30,965 $2.72 Million
Q4 2021

Feb 14, 2022

SELL
$79.7 - $88.13 $2.52 Million - $2.78 Million
-31,598 Reduced 50.96%
30,402 $2.66 Million
Q3 2021

Dec 08, 2021

BUY
$81.78 - $95.14 $4.48 Million - $5.21 Million
54,798 Added 760.87%
62,000 $5.05 Million
Q3 2021

Nov 05, 2021

SELL
$81.78 - $95.14 $1.89 Million - $2.2 Million
-23,115 Reduced 76.24%
7,202 $1.22 Million
Q2 2021

Aug 10, 2021

BUY
$85.24 - $94.15 $39,380 - $43,497
462 Added 1.55%
30,317 $2.77 Million
Q1 2021

May 12, 2021

SELL
$83.5 - $98.47 $325,149 - $383,442
-3,894 Reduced 11.54%
29,855 $2.55 Million
Q4 2020

Feb 11, 2021

SELL
$78.07 - $94.43 $21,156 - $25,590
-271 Reduced 0.8%
33,749 $3.19 Million
Q3 2020

Nov 09, 2020

SELL
$82.14 - $91.0 $67,272 - $74,529
-819 Reduced 2.35%
34,020 $2.96 Million
Q2 2020

Aug 13, 2020

BUY
$80.93 - $91.1 $482,342 - $542,956
5,960 Added 20.64%
34,839 $3.04 Million
Q1 2020

May 12, 2020

SELL
$70.67 - $99.01 $604,511 - $846,931
-8,554 Reduced 22.85%
28,879 $2.37 Million
Q4 2019

Jan 28, 2020

SELL
$84.35 - $95.37 $4,133 - $4,673
-49 Reduced 0.13%
37,433 $3.54 Million
Q3 2019

Oct 22, 2019

BUY
$85.54 - $94.26 $117,617 - $129,607
1,375 Added 3.81%
37,482 $3.26 Million
Q2 2019

Jul 18, 2019

BUY
$75.4 - $92.8 $99,000 - $121,846
1,313 Added 3.77%
36,107 $3.3 Million
Q1 2019

May 06, 2019

SELL
$75.32 - $86.15 $2.62 Million - $3 Million
-34,794 Reduced 50.0%
34,794 $3.34 Million
Q1 2019

May 01, 2019

BUY
$75.32 - $86.15 $2.7 Million - $3.09 Million
35,812 Added 106.03%
69,588 $6.68 Million
Q4 2018

Feb 13, 2019

SELL
$73.66 - $82.02 $99,882 - $111,219
-1,356 Reduced 3.86%
33,776 $2.9 Million
Q3 2018

Nov 14, 2018

BUY
$66.94 - $77.43 $50,271 - $58,149
751 Added 2.18%
35,132 $3.03 Million
Q2 2018

Aug 14, 2018

SELL
$64.91 - $73.36 $342,984 - $387,634
-5,284 Reduced 13.32%
34,381 $2.6 Million
Q1 2018

May 18, 2018

SELL
$70.39 - $84.15 $21,961 - $26,254
-312 Reduced 0.78%
39,665 $3.21 Million
Q4 2017

Feb 13, 2018

SELL
$72.33 - $77.64 $90,123 - $96,739
-1,246 Reduced 3.02%
39,977 $3.35 Million
Q3 2017

Nov 16, 2017

BUY
$74.14 - $77.27 $224,495 - $233,973
3,028 Added 7.93%
41,223 $3.55 Million
Q2 2017

Aug 15, 2017

BUY
N/A
38,195
38,195 $3.19 Million

Others Institutions Holding NVS

About NOVARTIS AG


  • Ticker NVS
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,151,000,064
  • Market Cap $224B
  • Description
  • Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...
More about NVS
Track This Portfolio

Track Moors & Cabot, Inc. Portfolio

Follow Moors & Cabot, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Moors & Cabot, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Moors & Cabot, Inc. with notifications on news.